

	Effective Date: 01/21/2026	Revision Date(s): 02/25/19, 02/18/22, 08/02/23, 07/31/24, 05/31/25, 07/25/25, 01/21/2026
Department: PHARMACY	MMC Review/ Approval Date(s): 03/15/22, 08/04/23, 08/01/24, 01/21/2026	Page(s): 14
Policy Number: 047.004 Title: Coverage Determination Policy for Antithymocyte Globulins <ul style="list-style-type: none"> • Atgam (Antithymocyte globulin equine) and Thymoglobulin (Antithymocyte globulin rabbit) 		

Regions: **Texas** **Florida** **New Mexico**

Impacted Areas:	
<input checked="" type="checkbox"/> Network Management/Provider Services	<input checked="" type="checkbox"/> Utilization Management
<input type="checkbox"/> Member services	<input type="checkbox"/> Case management
<input type="checkbox"/> Quality Management	<input type="checkbox"/> Disease management
<input type="checkbox"/> Credentialing	<input checked="" type="checkbox"/> Claims
<input type="checkbox"/> IT	<input type="checkbox"/> Human resources
<input type="checkbox"/> Administration	<input type="checkbox"/> Finance
<input type="checkbox"/> Compliance/delegation	<input checked="" type="checkbox"/> Pharmacy
<input type="checkbox"/> ALL	

Approved by: Megan Ortiz, MD FACOG Senior Medical Director		Date:
---	--	--------------

Reviewed by: Sherien Zaid, Pharm.D Director, Clinical Pharmacy		Date:
---	--	--------------

Available LCD/NCD/LCA:
CMS Local Coverage Determination for Texas (LCD): Immunosuppressive Drugs ([L33824](#))
CMS National Coverage Determination (NCD): Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) ([260.7](#))

Disclaimer:
WellMed applies criteria outlined in this policy to complement National Coverage Determination (NCD 260.7) and Local Coverage Determination (LCD L33824) and other CMS guidance related to the use of antithymocyte globulins. The use of this criteria ensures consistent and evidence-based decisions regarding medical necessity and appropriate use of these agents. The criteria aims to reduce inappropriate denials by providing standardized review parameters for when treatment is medically appropriate. By applying the criteria outlined in this policy, WellMed aims to prevent the use of antithymocyte globulin therapy in cases where it is not medically indicated, thereby reducing the risk of unnecessary immunosuppression, adverse effects such as leukopenia or thrombocytopenia, and downstream complications. The benefits of antithymocyte globulin therapy include its proven efficacy in preventing and treating acute renal allograft rejection and in managing

severe aplastic anemia in patients unsuitable for bone marrow transplantation. Potential clinical harms of applying the criteria within this policy may include denying access to therapy when otherwise indicated, potentially leading to treatment delays. However, the clinical benefits of using these criteria to supplement general coverage provisions are expected to outweigh any potential harms, as they promote consistent, evidence-based decision-making and reduce variability in coverage determinations.



WellMed Drug and Biologic Coverage Determination Policy

Title: Coverage Determination Policy for Antithymocyte Globulins

- **Atgam (Antithymocyte globulin equine) and Thymoglobulin (Antithymocyte globulin rabbit)**

Table of Contents	Page	Coverage Policy Number: 047.004
Coverage Determination (Initial/New Requests)	3	Line of Business: Medicare Part B
Coverage Determination (Renewal/Continuation of Therapy Requests)	5	Policy Type: Prior Authorization
FDA Approved Dose and Indication	6	
General Background	7	
Clinical Evidence	8	
HCPCS Code	10	
Acronyms	11	
References	12	
Policy History/Revision Information	14	

Coverage Determination:

Initial/New Requests

Note: For all requests, do not administer live vaccines to patients about to receive, receiving, or after treatment with ATGAM due to a potential of uncontrolled viral replication in the immunosuppressed patient.

Atgam and Thymoglobulin should be prescribed by or in consultation with nephrologist, transplant specialist, hematologist and/or oncologist.

WellMed Medical Management will cover **Atgam (Antithymocyte Globulin Equine)** as medically necessary when the following diagnosis specific criteria are met:

1. Treatment of Allograft rejection in patients who have received a renal transplant: **ALL** of the following must be met:
 - A. Patient has received a kidney transplant
 - B. Atgam will be administered with conventional therapy/immunosuppressants*
 - C. Dosing does not exceed FDA approved dosing: 10 to 15 mg/kg daily intravenously for 14 days; additional alternate-day therapy up to a total of 21 doses may be given.

2. Treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation: **ALL** of the following criteria must be met:
 - A. Provider has indicated patient is not suitable for a bone marrow transplant
 - B. Diagnosis of aplastic anemia is NOT secondary to any of the following: neoplastic disease, storage disease, myelofibrosis, Fanconi syndrome, exposure to myelotoxic agents or radiation.
 - C. Dosing does not exceed FDA approved dosing: 10 to 20 mg/kg daily intravenously for 8 to 14 days; additional alternate-day therapy up to a total of 21 doses may be given.

NOTE: The usefulness of Atgam has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation

WellMed Medical Management will cover **Thymoglobulin (Antithymocyte Globulin Rabbit)** as medically necessary when the following diagnosis specific criteria are met:

1. Prophylaxis of acute rejection in patients receiving a kidney transplant **ALL** of the following must be met:
 - A. Thymoglobulin will be administered with immunosuppressants*
 - B. Patient does NOT have any active acute or chronic infections
 - C. WBC or Platelet count has been provided
 - i. If WBC count is between 2,000- 3,000 cells/mm³ or platelet count is between 50,000-75,000 cells/mm³ Thymoglobulin dose should be reduced by one-half. Provider should consider stopping Thymoglobulin if WBC count falls below 2000 cells/mm³ or if platelet count falls below 50,000 cells/mm³.
 - D. Dose does NOT exceed 1.5 mg/kg of body weight administered daily for 4 to 7 days

2. Treatment of acute rejection in patients following a kidney transplant **ALL** of the following must be met:
 - A. Thymoglobulin will be administered with immunosuppressants*
 - B. Patient does NOT have any active acute or chronic infections
 - C. WBC or Platelet count has been provided
 - i. If WBC count is between 2,000- 3,000 cells/mm³ or platelet count is between 50,000-75,000 cells/mm³ Thymoglobulin dose should be reduced by one-half. Provider should consider stopping Thymoglobulin if WBC count falls below 2000 cells/mm³ or if platelet count falls below 50,000 cells/mm³.
 - D. Dose does NOT exceed 1.5 mg/kg of body weight administered daily for 7 to 14 days

Renewal/Continuation of Therapy Requests

WellMed Medical Management will cover **Atgam (Antithymocyte Globulin Equine)** for renewal as medically necessary when the following diagnosis- specific criteria are met:

1. Treatment of Allograft rejection in Renal Transplant patients OR Treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation, ALL of the following must be met:
 - A. Patient must meet initial coverage criteria
 - B. Patient has NOT experienced any allergic reactions during any prior ATGAM or equine gamma globulin administration
 - C. Request is for a max of 21 doses at FDA approved dosing

WellMed Medical Management will cover **Thymoglobulin (Antithymocyte Globulin Rabbit)** for renewal as medically necessary when the following criteria are met:

1. Prophylaxis or Treatment of acute rejection in patients following a kidney transplant, ALL of the following must be met:
 - A. Patient must meet initial coverage criteria
 - B. WBC or platelet count has been provided
 - i. If WBC count is between 2,000- 3,000 cells/mm³ or platelet count is between 50,000-75,000 cells/mm³ Thymoglobulin dose should be reduced by one-half. Provider should consider stopping Thymoglobulin if WBC count falls below 2000 cells/mm³ or if platelet count falls below 50,000 cells/mm³.
 - C. Request does NOT exceed 1.5 mg/kg daily AND 1 one of the following
 - i. Duration does not exceed 7 days for prophylaxis
 - ii. Duration does not exceed 14 days for treatment

FDA Approved Dose and Indication

Drug	Indication	Dosing
Atgam®	<ul style="list-style-type: none"> Treatment of Allograft rejection in patients who have received a renal transplant (administered with conventional therapy) 	<ul style="list-style-type: none"> 10 to 15 mg/kg daily intravenously for 14 days*
	<ul style="list-style-type: none"> Moderate to Severe Aplastic Anemia in patient's unsuitable for bone marrow transplant 	<ul style="list-style-type: none"> 10 to 20 mg/kg daily intravenously for 8 to 14 days*
	*Additional alternate-day therapy up to a total of 21 doses may be given for both indications	
Thymoglobulin®	<ul style="list-style-type: none"> Prophylaxis of acute rejection in patients following a kidney transplant (In combination with other immunosuppressive agents) 	<ul style="list-style-type: none"> 1.5 mg/kg of body weight administered daily for 4 to 7 days
	<ul style="list-style-type: none"> Treatment of acute rejection in patients following a kidney transplant (In combination with other immunosuppressive agents) 	<ul style="list-style-type: none"> 1.5 mg/kg of body weight administered daily for 7 to 14 days <p>Dose Adjustment:</p> <ul style="list-style-type: none"> WBC count 2,000-3,000 cells/mm³ or platelet count is 50,000-75,000 cells/mm³: <u>Reduce dose by 50%.</u> WBC count below 2000 cells/mm³ or platelet count below 50,000 cells/mm³: <u>Consider discontinuing therapy.</u>

General Background

Antithymocyte globulins (ATG) are polyclonal antibodies, which appear to cause immunosuppression through the elimination of antigen-reactive T lymphocytes. ATG is used to treat and prevent organ rejection in renal transplant patients and to treat severe aplastic anemia.

Since ATG is an immunosuppressant, patients should be monitored closely for infections, including cytomegalovirus (CMV). ATG can also cause hematologic toxicity including leukopenia and thrombocytopenia, which may necessitate dose reduction or discontinuation. Other common side effects include chills, headache, arthralgia, and dermatological reactions. Anaphylaxis and hypersensitivity has occurred rarely with ATG, so skin testing is recommended prior to the first dose. All patients receiving ATG should be monitored closely for adverse reactions to include at a minimum: Lymphocyte count (total lymphocyte and/or T-cell subset), CBC with differential and platelet count; vital signs during administration; and signs and symptoms of infection.

There are two ATG products on the market Atgam and Thymoglobulin, which are used for different indications. Antithymocyte globulin products are **NOT** interchangeable. Doses vary for each product due to differences in protein composition and concentration.

Atgam® has a US Boxed warning that it may cause anaphylaxis when injected intravenously. Although antithymocyte globulin (equine) is processed to reduce the level of antibodies that will react to non-T cells, health care providers should be prepared for the potential risk of anaphylaxis and monitor for signs/symptoms during infusion and for at least 24 hours after infusion.

Thymoglobulin® has a US Boxed warning that it should only be used by physicians experienced in immunosuppressive therapy in transplantation.

*Examples of conventional therapy/immunosuppressants used in renal transplant patients

- Tacrolimus (Prograf)
- Belatacept (Nulojix)
- Cyclosporine (SandImmune)
- Cyclosporine, modified (Neoral)
- Mycophenolate mofetil (Cellcept)
- Mycophenolic acid (Myfortic)
- Azathioprine (Imuran)
- Sirolimus (Rapamune)
- Steroids: Prednisone, methylprednisolone

Clinical Evidence

In a multicenter, double-blind, randomized trial, antithymocyte globulin (rabbit) was shown to be superior to antithymocyte globulin (equine) in reversing acute rejection and preventing subsequent episodes (Gaber 1998). Based on data from studies (including 10 years follow up) comparing ATG (rabbit) to ATG (equine) for induction, ATG (rabbit) has emerged as the T-cell lymphocyte depleting induction therapy of choice over ATG (equine) in adult kidney transplantation due to its improved efficacy and lower incidence of acute rejection (Brennan 1999; Hardinger 2008).

A randomized controlled trial of the use of Atgam as a substitute for standard therapy for treatment of the first acute rejection episode was conducted at one transplant center in recipients of living related renal allografts. A total of 22 patients were studied; 11 in each of the two treatment groups [Atgam versus standard therapy (bolus doses of Solu-Medrol)]. Patients randomized to the Atgam group received 14–21 doses of Atgam therapy, starting on the day the rejection was diagnosed. Atgam was administered daily according to a dose-by-rosette regimen, which resulted in a mean daily dose of approximately 15 mg/kg. Patients randomized to the control group received Solu-Medrol at a dosage of 15 mg/kg starting on the day the rejection was diagnosed, administered either daily or on alternate days for 3 to 7 doses to complete a maximum total dose of 5,000 mg for the course of the rejection episode. In this study, Atgam was at least effective as standard therapy for treatment of acute allograft rejection.

Results from randomized controlled trials in patients with first acute renal allograft rejection episodes refractory to conventional steroid therapy have demonstrated that Atgam, when administered in conjunction with standard therapy, yields efficacy results superior to those of standard therapy alone.

The use of Atgam for the treatment of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation is based on data from three controlled studies. Please see package insert for detailed description of all three clinical studies.

In a randomized trial in cadaveric recipients with a first acute renal allograft rejection episode at the time of diagnosis, antithymocyte globulin equine administered with standard therapy resulted in significant improvements in rejection resolution and functional graft survival with no significant difference seen in patient survival. In another study in living, related renal transplant recipients, there was no significant difference seen in rate of rejection resolution, functional graft survival, or patient survival. In a study of patients with first renal allograft rejection episode refractory to conventional steroid therapy, when antithymocyte globulin equine was administered with standard therapy, there was significant improvements in functional graft survival and patient's survival.

In a systematic review and meta-analysis of 6 randomized trials in 568 patients, there was no significant benefit with rabbit or equine antithymocyte globulin (ATG) for overall survival (496 patients in 5 studies) or the incidence of relapse (255 patients in 2 studies) when used for prophylaxis of graft-versus-host disease following allogeneic stem cell or bone marrow transplantation for hematological diseases. In a subgroup analysis, prophylaxis with equine ATG did not significantly reduce the incidence of all grades or grades II to IV acute graft-versus-host disease

HCPCS Code

HCPCS Code	Description
J7504	Atgam (Antithymocyte globulin equine) Intravenous Solution, 250mg
J7511	Thymoglobulin (Antithymocyte globulin rabbit) Intravenous Powder for Solution, 25 MG

Acronyms

ATG = Antithymocyte Globulin

CMV = Cytomegalovirus

SAA = Severe Aplastic Anemia

HSCT = Hematopoietic Stem Cell Transplant

NCD = National Coverage Determination

LCD = Local Coverage Determination

WBC= White Blood Cell Count

References

1. Atgam In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> Accessed on 05/06/25.
2. Thymoglobulin In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> Accessed on 05/06/25.
3. Atgam [prescribing information]. intravenous injection solution, equine thymocyte immune globulin intravenous injection solution . Pharmacia & Upjohn Co. A subsidiary of Pfizer Inc. NY, NY 10001. Revised : May 2023
4. Thymoglobulin [prescribing information]. intravenous injection solution, anti-thymocyte globulin (rabbit) intravenous injection solution. Genzyme Corporation. Cambridge, MA. Revised: 03/2023
5. Atgam Prescribing Information. New York, NY: Pzifer; May 2018. Available at file:///C:/Users/Downloads/20210812_bd545ba1-2366-4df1-bd67-10dfd7632b54%20(7).pdf
6. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published correction appears in Transplantation 1999;67(10):1386]. Transplantation.
7. CMS National Coverage Determination (NCD): Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) (260.7). Available at: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=148> Accessed December 09, 2021.
8. CMS Local Coverage Determination (LCD): Immunosuppressive Drugs (L33824). Accessed at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33824&DocID=L33824> Accessed December 09, 2021.
9. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430.
10. Kao SY, Xu W, Brandwein JM, Lipton JH, Messner HA, Minden MD, Schimmer AD, Schuh AC, Yee K, Gupta V . Outcomes of older patients (>or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol. 2008;143(5):738.
11. Hardinger, K. and Brennan, D. Kidney transplantation in adults: Maintenance immunosuppressive therapy. In: Post TW, ed. *UpToDate*. UpToDate; 2021. Accessed Decmeber 14, 2020. https://www.uptodate.com/contents/kidney-transplantation-in-adults-maintenance-immunosuppressivetherapy?search=immunosuppressive%20drugs&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2
12. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study Group . Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236. Epub 2002 Oct 10.

13. Scheinberg P, Townsley D, Dumitriu B, Scheinberg P, Weinstein B, Rios O, Wu CO, Young NS. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. *Am J Hematol*. 2014 May;89(5):467-9. Epub 2014 Mar 7.
14. Schrier, S. Treatment of aplastic anemia in adults. UpToDate®. Accessed at https://www.uptodate.com/contents/treatment-of-aplastic-anemia-inadults?source=search_result&search=aplastic%20anemia&selectedTitle=2~150#H12. Accessed on February 25, 2019.
15. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. *JAMA*. 2003;289(9):1130–1135.
16. Thymoglobulin Prescribing Information. Cambridge, MA: Genzyme Corporation; April 2020. Available at: <http://products.sanofi.us/Thymoglobulin/Thymoglobulin.pdf>. Accessed December 11, 2021
17. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. *Transplantation* 1998; 66:29.
18. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. *Transplantation*. 2008;86(7):947-952. [PubMed 18852661]

Policy History/Revision Information

Date Revised	Type of Changes (Significant or Minor)	List Significant Changes and/or Status of policy
07/07/17	Significant	New coverage criteria created.
02/25/19	Minor	Deleted off-label indication and dosing for Thymoglobulin. Added Wellmed disclaimer and CMS LCD/NCD statement. Updated references-Eric McDermott, PharmD
02/18/22	Significant	Created criteria for initial and renewal requests for Atgam and Thymoglobulin's FDA approved indications. Added FDA Dosing table and chart of conventional immunosuppressive therapies. Updated General Background, Clinical Evidence, and References. MVader, PharmD.
08/02/23	Minor	Updated the FDA Approved Dose table, updated HCPCS Code table and References. C. Osidele, Pharm.D.
07/31/2024	Minor	Annual revision, LCD (33824) hyperlink updated – Pathik Tripathi, PharmD
05/31/25	Minor	Annual revision, LCD (33824) and NCD (260.7) hyperlink updated, added Nulojix to conventional therapy. – L. Bernstein, Pharm.D.
07/25/25	Minor	Updated disclaimer section. S.Zaid, PharmD